COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00346008
Recruitment Status : Completed
First Posted : June 29, 2006
Last Update Posted : May 30, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.

Condition or disease Intervention/treatment
Melanoma (Skin) Genetic: mutation analysis Other: high performance liquid chromatography Other: laboratory biomarker analysis Other: questionnaire administration

Detailed Description:


  • Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
  • Assess the feasibility of mutation detection using sequencing and HPLC.
  • Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.

OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2500 participants
Official Title: Genetic Epidemiologic Studies of Melanoma in Iceland
Study Start Date : October 2005
Actual Primary Completion Date : December 2008
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Primary Outcome Measures :
  1. Feasibility to identify melanoma
  2. Feasibility to detect mutation
  3. Ability to create datasets

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes


  • Patients diagnosed with melanoma and selected family members are eligible to participate
  • Must live in Iceland


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00346008

Layout table for location information
Iceland Genomics Corporation
Reykjavik, Iceland, 105
Sponsors and Collaborators
Iceland Genomics Corporation
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Alisa Goldstein, PhD National Cancer Institute (NCI)
Layout table for additonal information Identifier: NCT00346008    
Obsolete Identifiers: NCT00482534
Other Study ID Numbers: NBCI-03-033-CM
CDR0000551606 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: June 29, 2006    Key Record Dates
Last Update Posted: May 30, 2013
Last Verified: December 2008
Keywords provided by National Cancer Institute (NCI):
recurrent melanoma
stage I melanoma
stage II melanoma
stage III melanoma
stage IV melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas